Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$11.69 USD
-0.25 (-2.09%)
Updated Sep 29, 2023 04:00 PM ET
After-Market: $11.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CPRX 11.69 -0.25(-2.09%)
Will CPRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know
Other News for CPRX
JW Asset Management, LLC Increases Stake in TerrAscend Corp
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. stock falls Thursday, underperforms market
Catalyst Pharmaceuticals Inc. stock rises Wednesday, outperforms market
JW Asset Management, LLC Boosts Stake in TerrAscend Corp